Literature DB >> 8319319

Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans.

I M McIntyre1, T R Norman, G D Burrows, S M Armstrong.   

Abstract

Six healthy volunteers were given a 2-mg dose of alprazolam at 21:00 h and hourly blood samples were collected until 08:00 h the following morning. A control night of hourly blood sampling was undertaken 7 days before Plasma was analyzed for melatonin, cortisol, and alprazolam concentrations. Melatonin concentrations were significantly suppressed by alprazolam at 23:00, midnight, 01:00, 06:00, and 07:00 h. A trend toward suppression was evident from 02:00 to 05:00 h. Cortisol concentrations were also suppressed by alprazolam at several times throughout the night (01:00-04:00 h). Plasma alprazolam levels showed a peak at 3 h and remained relatively high 19-20 h after the dose. The significance of melatonin suppression by alprazolam is discussed in terms of benzodiazepine binding sites and GABA minergic transmission in the human pineal gland, suprachiasmatic nuclei, and retina. Plasma cortisol suppression has been reported for other benzodiazepine drugs, but conflicting data exist for alprazolam. The present results do not support the proposed inhibitory effect of melatonin on the hypothalamic-pituitary-adrenal (HPA)-axis. It is suggested that there is no simple direct relationship between melatonin and the HPA axis in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319319     DOI: 10.3109/07420529309073889

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  11 in total

1.  General anesthesia for surgery influences melatonin and cortisol levels.

Authors:  Edward Ram; Tali H Vishne; Talia Weinstein; Benzion Beilin; Zeev Dreznik
Journal:  World J Surg       Date:  2005-07       Impact factor: 3.352

Review 2.  The neurobiology and genetics of impulse control disorders: relationships to drug addictions.

Authors:  Judson A Brewer; Marc N Potenza
Journal:  Biochem Pharmacol       Date:  2007-07-03       Impact factor: 5.858

Review 3.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

4.  Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder.

Authors:  Nunzio Pomara; Lisa M Willoughby; John J Sidtis; Thomas B Cooper; David J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

Review 5.  Medication for sleep-wake disorders.

Authors:  G Stores
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 6.  Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

Review 7.  Melatonin in perioperative medicine: Current perspective.

Authors:  Souvik Maitra; Dalim Kumar Baidya; Puneet Khanna
Journal:  Saudi J Anaesth       Date:  2013-07

8.  Melatonin and cortisol exhibit different circadian rhythm profiles during septic shock depending on timing of onset: a prospective observational study.

Authors:  Eleni N Sertaridou; Ioanna G Chouvarda; Konstantinos I Arvanitidis; Eirini K Filidou; George C Kolios; Ioannis N Pnevmatikos; Vasilios E Papaioannou
Journal:  Ann Intensive Care       Date:  2018-12-04       Impact factor: 6.925

9.  'Chronomics' in ICU: circadian aspects of immune response and therapeutic perspectives in the critically ill.

Authors:  Vasilios Papaioannou; Alexandre Mebazaa; Benoît Plaud; Matthieu Legrand
Journal:  Intensive Care Med Exp       Date:  2014-05-14

10.  Diazepam and fluoxetine decrease the stress response in zebrafish.

Authors:  Murilo Sander de Abreu; Gessi Koakoski; Daiane Ferreira; Thiago Acosta Oliveira; João Gabriel Santos da Rosa; Darlan Gusso; Ana Cristina Varrone Giacomini; Angelo Luis Piato; Leonardo José Gil Barcellos
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.